DelveInsight’s analysis reveals that the PD-1 and PD-L1 inhibitors pipeline features over 180 active companies engaged in the development of more than 200 therapeutic candidates targeting PD-1 and PD-L1 pathways.
PD-1 and PD-L1 Inhibitors Overview:
PD-1 and PD-L1 inhibitors are classes of immunotherapy drugs designed to enhance the immune system’s capacity to recognize and destroy cancer cells. The PD-1 receptor, found on T cells, and its ligand PD-L1, expressed on tumor and certain normal cells, serve as immune checkpoints that limit T cell activity. Many cancers exploit this mechanism to evade immune detection. PD-1 inhibitors block the PD-1 receptor, while PD-L1 inhibitors target the PD-L1 protein—both effectively disrupting the suppressive signaling between the two. This reactivation of T cells enables them to identify and attack malignant cells more effectively.
These inhibitors act by interfering with a crucial immune regulatory pathway that tumors often use to suppress immune responses. Normally, PD-1 binding to PD-L1 inhibits T cell activity, promoting immune tolerance. Drugs such as nivolumab and pembrolizumab (PD-1 inhibitors) bind to PD-1 receptors, while atezolizumab and durvalumab (PD-L1 inhibitors) target PD-L1 on cancer cells. By blocking this “off switch,” these therapies sustain T cell activation, proliferation, and tumor-killing ability. As a result, PD-1 and PD-L1 inhibitors have become pivotal in modern oncology, significantly improving outcomes in cancers like melanoma, non-small cell lung cancer, and renal cell carcinoma.
Request for a detailed insights report on PD-1 and PD-L1 Inhibitors pipeline insights
"PD-1 and PD-L1 Inhibitors Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the PD-1 and PD-L1 Inhibitors Therapeutics Market.
Key Takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report
-
DelveInsight’s PD-1 and PD-L1 Inhibitors Pipeline Report highlights a dynamic landscape featuring over 180 companies actively developing 200+ therapeutic candidates targeting PD-1 and PD-L1 pathways.
-
In February 2025, Innovent Biologics announced that its investigational therapy IBI363 received a second Fast Track Designation (FTD) from the U.S. FDA for treating unresectable, locally advanced, or metastatic squamous non-small cell lung cancer (sqNSCLC) in patients whose disease progressed after anti-PD-(L)1 therapy and platinum-based chemotherapy. That same month, Shanghai Henlius Biotech dosed the first patient in a Phase II clinical trial of HLX43, a PD-L1-targeting antibody-drug conjugate (ADC).
-
Earlier, in January 2025, Pfizer reported positive topline results from its Phase III CREST trial, evaluating sasanlimab in combination with Bacillus Calmette-Guérin (BCG). The study met its primary endpoint of event-free survival (EFS), demonstrating a statistically significant and clinically meaningful improvement.
-
Key players such as Compass Therapeutics, Aurigene Discovery Technologies, RemeGen, Inhibrx, Effector Therapeutics, CytomX Therapeutics, Innovent Biologics, GlaxoSmithKline, Biocad, Genentech, Bristol Myers Squibb, and Merck are advancing innovative PD-1/PD-L1 inhibitors to enhance cancer treatment outcomes.
-
Promising candidates under development include CTX-8371, CA-327, RC-98, AUR-106, INBRX-105, Tomivosertib, CX-072, IBI-323, Jemperli, BCD-100, Tecentriq, Opdivo, Keytruda, and others, reflecting the depth and diversity of the current pipeline.
PD-1 and PD-L1 Inhibitors Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the PD-1 and PD-L1 Inhibitors Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PD-1 and PD-L1 Inhibitors treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the PD-1 and PD-L1 Inhibitors market.
Download our free sample page report on PD-1 and PD-L1 Inhibitors pipeline insights
PD-1 and PD-L1 Inhibitors Emerging Drugs
-
CTX-8371: Compass Therapeutics
-
CA 327: Aurigene Discovery Technologies
-
RC-98: RemeGen
-
AUR-106: Aurigene Discovery Technologies
-
INBRX 105: Inhibrx
-
Tomivosertib: Effector Therapeutics
-
CX-072: CytomX Therapeutics
-
IBI 323: Innovent Biologics
-
Jemperli: GlaxoSmithKline
-
BCD-100: Biocad
-
TECENTRIQ: Genentech
-
Opdivo: Bristol Myers Squibb
-
KEYTRUDA: Merck
PD-1 and PD-L1 Inhibitors Companies
The report provides an in-depth commercial evaluation of the profiled drugs, highlighting trends in deal values across collaborations, licensing agreements, partnerships, and acquisitions. It further delivers a detailed sub-segmentation, categorizing different types of partnerships—such as company-to-company collaborations, company-academic alliances, and acquisitions—presented in a clear, tabular format.
DelveInsight’s report covers around 75+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
PD-1 and PD-L1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
PD-1 and PD-L1 Inhibitors Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging PD-1 and PD-L1 Inhibitors Therapies and Key Companies: PD-1 and PD-L1 Inhibitors Clinical Trials and advancements
PD-1 and PD-L1 Inhibitors Pipeline Therapeutic Assessment
-
PD-1 and PD-L1 Inhibitors Assessment by Product Type
-
PD-1 and PD-L1 Inhibitors By Stage
-
PD-1 and PD-L1 Inhibitors Assessment by Route of Administration
-
PD-1 and PD-L1 Inhibitors Assessment by Molecule Type
Download PD-1 and PD-L1 Inhibitors Sample report to know in detail about the PD-1 and PD-L1 Inhibitors treatment market @ PD-1 and PD-L1 Inhibitors Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. PD-1 and PD-L1 Inhibitors Current Treatment Patterns
4. PD-1 and PD-L1 Inhibitors - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. PD-1 and PD-L1 Inhibitors Late-Stage Products (Phase-III)
7. PD-1 and PD-L1 Inhibitors Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. PD-1 and PD-L1 Inhibitors Discontinued Products
13. PD-1 and PD-L1 Inhibitors Product Profiles
14. PD-1 and PD-L1 Inhibitors Key Companies
15. PD-1 and PD-L1 Inhibitors Key Products
16. Dormant and Discontinued Products
17. PD-1 and PD-L1 Inhibitors Unmet Needs
18. PD-1 and PD-L1 Inhibitors Future Perspectives
19. PD-1 and PD-L1 Inhibitors Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the PD-1 and PD-L1 Inhibitors Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/